

FOR IMMEDIATE RELEASE

Japan's Corundum Systems Biology to Invest in *Health for life Capital II™* Fund

Forms Strategic Partnership for Japan with the Fund's Seventure Partners

Tokyo, August 31, 2020 -- Corundum Systems Biology Inc., a Japan-based company dedicated to facilitating microbiome research and business creation, announces the CSB-1 (Luxembourg) SCSp ("CSB-1 (LUX) SCSp") Fund will invest in Seventure Partners' *Health for life Capital II™* (HFL II) Fund. Corundum Systems Biology and Seventure Partners will also become strategic partners for Japan, paving way for enhanced access to information in microbiome innovation and potential.

Seventure Partners, based in France and acknowledged as a world leader in financing innovation, first launched in March 2014 the groundbreaking HFL I, a fund focused on the microbiome and health and nutrition sectors. The successor fund, HFL II was launched in Q1 2019. To date, HFL II has attracted strategic investments from active food, nutrition and healthcare players including Danone, Novartis, Lesaffre, Unigrains and Bel as well as many institutional financial investors. The HFL II fund target of €200 million (approximately JPY24 billion) has already been oversubscribed and the fund now targets €250-300 million for the final close which is expected end of 2020.

Through the strategic partnership with Seventure, Corundum Systems Biology will help expand business investment opportunities in Japan and Asia for HFL and HFLII microbiome portfolio companies.

Corundum Systems Biology Inc., established in Japan on April 30, 2020, has three key business focus:

- Develop biometric database and data analysis platform related to microbiome
- Develop new businesses in the field of microbiome
- Support facilitation and hastening of R&D related to microbiome

The CSB-1 (LUX) SCSp Fund, with €20 million (approximately JPY2.4 billion) commitments under management, was established in Luxembourg in July 2020.

Contact: marketing@csb.co.jp

Public Relations, Corundum Systems Biology Inc.

(03)5404-8590

Reference

About Health for Life Capital™

Health for Capital™ is the first venture capital fund focused mainly on investments “beyond the pill” in the microbiome and nutrition space. Europe is the primary focus of the fund, but it also invests in North America, Asia and Israel. The €160 million first fund and the €250 million second fund attracted strategic investments from prestigious organizations including Danone, Novartis, a US based global food ingredient provider, Lesaffre, Tornier, Tereos, Unigrains and Bel, as well as financial institutions and entrepreneurs. Health for Life Capital™ is managed by Seventure Partners' Life Sciences team.

About Seventure Partners

The €750 million net commitments under management at end of 2018, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has been investing in successfully in innovative businesses with high growth potential in two fields: life sciences across Europe, Israel, Asia and North America, and digital technologies in France and Germany. (www.seventure.fr/en)

About Corundum Systems Biology Inc.

Corundum Systems Biology, established in Japan in April 2020, aspires to become an Innovation Hub in the field of microbiome, a critical field with potential to unlock next-generation life science technologies and bettering human health and quality of life. The company focuses on microbiome in three business areas: development of new business, development of biometric database and data analysis platforms, and grant- giving to facilitate and hasten R&D. (<https://www.csb.co.jp/>)